What's Happening?
The Department of Health and Social Care (DHSC) has announced the successful acquisition of additional volumes of pancreatic enzyme replacement therapy (PERT) for the year 2025. This development comes
in response to ongoing supply disruptions affecting all PERT brands in the UK, which were first highlighted in a national patient safety alert in May 2024. The alert advised pharmacists to limit PERT prescriptions to one month's supply due to shortages. PERT is crucial for individuals with pancreatic insufficiencies, aiding digestion and nutrient absorption. The DHSC is actively collaborating with suppliers to address both immediate and long-term supply challenges, ensuring continuous access to these essential medications. The department is also engaging with specialist importers to source unlicensed stock to fill market gaps. Manufacturers like Viatris are planning to increase production capacity, with new facilities expected to be operational by 2026.
Why It's Important?
The assurance of PERT supply is vital for patients with conditions such as pancreatitis, pancreatic cancer, and cystic fibrosis, who rely on these medications for daily digestive support. The shortages have previously led to significant health issues and stress among patients, as evidenced by a survey conducted by the Cystic Fibrosis Trust. The survey revealed that 43% of respondents experienced health problems due to PERT shortages, with 80% reporting stress and anxiety. The DHSC's efforts to secure additional supplies and work with manufacturers to increase production capacity are crucial steps in mitigating these impacts. Ensuring stable supply chains for essential medications not only supports patient health but also alleviates pressure on healthcare providers managing these conditions.
What's Next?
The DHSC will continue its collaboration with manufacturers and importers to resolve supply issues and maintain stable PERT availability. The construction of new manufacturing facilities by companies like Viatris is expected to enhance production capacity by 2026, with finished products available for distribution by early 2027. Meanwhile, healthcare professionals and organizations like Pancreatic Cancer UK and the Cystic Fibrosis Trust are actively engaging with the government to push for further improvements in supply chain management. These efforts aim to prevent future shortages and ensure uninterrupted access to vital medications for affected patients.
Beyond the Headlines
The ongoing PERT supply challenges highlight the broader issue of pharmaceutical supply chain vulnerabilities, which can significantly impact patient care and healthcare systems. The situation underscores the importance of strategic planning and investment in manufacturing infrastructure to prevent similar shortages in the future. Additionally, it raises ethical considerations regarding the equitable distribution of essential medications and the need for robust contingency plans to safeguard patient health during supply disruptions.
